Knight Therapeutics Introduces JORNAY PM™ for ADHD Treatment
Introducing JORNAY PM™ to the Canadian Market
Knight Therapeutics Inc. (TSX: GUD) has exciting news for families managing Attention-Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12. The company recently launched JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. This innovative product offers a new treatment option designed to improve the management of ADHD symptoms.
Understanding ADHD and Its Impact
Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder affecting both children and adults. Studies estimate its prevalence at around 5-9% in children and adolescents, and 3-5% in adults. Individuals with ADHD can struggle with inattention, hyperactivity, and impulsivity, challenges that can hinder daily functioning and overall quality of life. Given the ongoing need for adequate symptom management, it's essential to explore new and effective treatments like JORNAY PM™.
What Makes JORNAY PM™ Unique?
What sets JORNAY PM™ apart from other medications is its unique evening dosing regimen. Dr. Doron Almagor, a recognized Child and Adolescent Psychiatrist, emphasizes that managing ADHD effectively involves helping children transition into their day as smoothly as possible. JORNAY PM™ is formulated with an innovative delayed-release technology that ensures a gradual onset of effect at waking. This allows for therapeutic benefits not just at the start of the day, but continuing into the evening as well.
The Benefits of Extended Release
JORNAY PM™ employs a dual-layer system — a delayed-release layer that ensures the active ingredient is released at the right time, followed by an extended-release layer that maintains symptom control throughout the day. This fascinating mechanism allows children to experience relief from ADHD symptoms from morning until evening, making daily tasks and interactions much more manageable.
Market Insights and Demand for ADHD Treatments
With awareness of ADHD growing and the need for effective treatments increasing, the Canadian ADHD market was estimated at approximately $1.25 billion, with the methylphenidate segment growing at a compound annual growth rate (CAGR) exceeding 14% over recent years. Such statistics highlight the ongoing opportunity for innovative solutions like JORNAY PM™ to fulfill unmet medical needs.
Clinical Trial Success
JORNAY PM™ underwent thorough testing in two multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trials. Both studies reported statistically significant improvements in ADHD symptom management upon waking and throughout the day, affirming the product's effectiveness. Results indicated common side effects included insomnia, decreased appetite, and slight increases in blood pressure, which were expected and manageable.
Commitment to ADHD Management and Community
Samira Sakhia, President and CEO of Knight Therapeutics, expressed her enthusiasm about the product launch, stating, "We are excited to introduce JORNAY PM™ to the Canadian market, thereby offering a new and advanced treatment option for ADHD patients and their families." This commitment reflects Knight Therapeutics' dedication to supporting the ADHD community by enhancing daily symptom management.
Conclusion: A Pioneering Step Forward
As ADHD remains a complex condition requiring ongoing care, the introduction of JORNAY PM™ symbolizes a significant step forward for pediatric treatment options in Canada. With this innovative product, Knight Therapeutics is well-positioned to lead the charge in improving the lives of children facing the challenges of ADHD.
Frequently Asked Questions
What is JORNAY PM™?
JORNAY PM™ is an extended-release formulation of methylphenidate designed specifically for managing ADHD symptoms in children aged 6 to 12 years in Canada.
How does JORNAY PM™ work?
This medication utilizes a unique delayed-release technology that provides symptom control starting at waking and continues throughout the evening, enabling better daily management of ADHD.
What are the common side effects of JORNAY PM™?
Common side effects observed in clinical trials include insomnia, decreased appetite, and slight increases in blood pressure.
Why is the launch of JORNAY PM™ significant?
The launch is significant because it provides families with a new treatment option that can significantly improve the management of ADHD, addressing an important medical need in the market.
How can I learn more about Knight Therapeutics?
You can learn more about Knight Therapeutics and their products by visiting their official website at www.knighttx.com.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.